Unique ID issued by UMIN | UMIN000034990 |
---|---|
Receipt number | R000039904 |
Scientific Title | The retrospective analysis of hyperprogressive disease during nivolumab chemotherapy in metastatic gastric cancer |
Date of disclosure of the study information | 2018/11/30 |
Last modified on | 2021/12/01 15:23:04 |
The retrospective analysis of hyperprogressive disease during nivolumab chemotherapy in metastatic gastric cancer
Hyperprogression during nivolumab therapy in gastric cancer
The retrospective analysis of hyperprogressive disease during nivolumab chemotherapy in metastatic gastric cancer
Hyperprogression during nivolumab therapy in gastric cancer
Japan |
Gastric Cancer
Medicine in general | Hematology and clinical oncology |
Malignancy
NO
To clarify the prevalence and background of hyperprogressive disease treated with nivolumab monotherapy in advanced gastric cancer patients with refractotry to, or intolerant of at least two previous chemotherapy regimens
Efficacy
To explore the prevalence and background of hyperprogressive disease
To explore the efficacy of nivolumab such as response, progression free survival and overall survival
Others,meta-analysis etc
20 | years-old | <= |
Not applicable |
Male and Female
1) Histologically confirmed adenocarcinoma of the stomach or esophago-gastric junction
2) Patents treated with at least two or more lines of previous chemotherapy
3) Treatment with nivolumab monotherapy started between September 22, 2017 and October 31, 2018 in advanced gastric cancer patients with refractotry to, or intolerant of at least two previous chemotherapy regimens (previous chemotherapy must be refractory)
4) Having at least one measurable target lesion defined by CT or MRI
5) CT judged to be refractory to previous chemotherapy can be the baseline data of nivolumab therapy
6) No prior treatment with anti-PD-1 antibody, anti-PD-L1 antibody, anti-CTLA-4 antibody, or other therapeutic antibodies or pharmacotherapies for the regulation of T-cells
7) No systemic corticosteroids (10 mg/day or more) or immune-suppressants administered concurrently or within 14 days before registration
Synchronous or metachronous malignancies
200
1st name | |
Middle name | |
Last name | Narikazu Boku |
National Cancer Center Hospital
Gastrointestinal Medical Oncology Division
5-1-1, Tsukiji, Chuo-ku, Tokyo 104-0045, Japan
03-3542-2511
nboku@ncc.go.jp
1st name | |
Middle name | |
Last name | Masahiko Aoki |
National Cancer Center Hospital
Gastrointestinal Medical Oncology Division
5-1-1, Tsukiji, Chuo-ku, Tokyo 104-0045, Japan
03-3542-2511
masaoki@ncc.go.jp
National Cancer Center Hospital
none
Other
NO
恵佑会札幌病院、富山大学附属病院、石川県立中央病院、筑波大学附属病院、埼玉県立がんセンター、慶應義塾大学病院、国立がん研究センター中央病院、虎の門病院、千葉県がんセンター、佐久医療センター、静岡県立静岡がんセンター、愛知県がんセンター中央病院、大阪医科大学附属病院、大阪市立総合医療センター、大阪急性期総合医療センター、大阪国際がんセンター、近畿大学医学部奈良病院、姫路赤十字病院、高知医療センター、九州がんセンター、九州大学病院、JCHO九州病院、宮崎大学医学部附属病院
2018 | Year | 11 | Month | 30 | Day |
Partially published
243
No longer recruiting
2018 | Year | 11 | Month | 08 | Day |
2018 | Year | 11 | Month | 08 | Day |
2018 | Year | 11 | Month | 08 | Day |
2020 | Year | 11 | Month | 08 | Day |
2020 | Year | 11 | Month | 08 | Day |
2020 | Year | 11 | Month | 08 | Day |
none
2018 | Year | 11 | Month | 25 | Day |
2021 | Year | 12 | Month | 01 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000039904
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |